

# MEDICAL ASSISTANCE BULLETIN

| ISSUE DATE                                     | EFFECTIVE DATE           | NUMBER  |  |
|--|--------------------------|---|--|
| November 17, 2021                              | January 3, 2022          | *See below  |  |
| SUBJECT  |                          | BY  |  |
| Prior Authorization of SI<br>Pharmacy Services | keletal Muscle Relaxants | - Sally A. Kozak, Deputy Secretary<br>Office of Medical Assistance Programs |  |

**IMPORTANT REMINDER:** All providers must revalidate the Medical Assistance (MA) enrollment of each service location every 5 years. Providers should log into PROMISe to check the revalidation dates of each service location and submit revalidation applications at least 60 days prior to the revalidation dates. Enrollment (revalidation) applications may be found at: <a href="https://www.dhs.pa.gov/providers/Providers/Pages/PROMISe-Enrollment.aspx">https://www.dhs.pa.gov/providers/Providers/Pages/PROMISe-Enrollment.aspx</a>.

# PURPOSE:

The purpose of this bulletin is to issue updated handbook pages that include the requirements for prior authorization and the type of information needed to evaluate the medical necessity of prescriptions for Skeletal Muscle Relaxants submitted for prior authorization.

# SCOPE:

This bulletin applies to all licensed pharmacies and prescribers enrolled in the Medical Assistance (MA) Program. The guidelines to determine the medical necessity of Skeletal Muscle Relaxants will be utilized in the fee-for-service delivery system and by the MA managed care organizations (MCOs) in Physical Health HealthChoices and Community HealthChoices. Providers rendering services in the MA managed care delivery system should address any questions related to the prior authorization of Skeletal Muscle Relaxants to the appropriate MCO.

#### **BACKGROUND/DISCUSSION:**

| *01-21-54 | 09-21-53 | 27-21-43 | 33-21-53 |
|-----------|----------|----------|----------|
| 02-21-39  | 11-21-42 | 30-21-47 |          |
| 03-21-39  | 14-21-42 | 31-21-56 |          |
| 08-21-56  | 24-21-50 | 32-21-39 |          |

COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO:

The appropriate toll-free number for your provider type.

Visit the Office of Medical Assistance Programs website at

https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/Contact-Informationfor-Providers.aspx. The Department of Human Services (Department) is updating the prescriptions that require prior authorization and corresponding medical necessity guidelines for Skeletal Muscle Relaxants to remove the requirement for prior authorization of Skeletal Muscle Relaxants that represent a therapeutic duplication. There are no other changes to the medical necessity guidelines.

The revisions to the guidelines to determine medical necessity of prescriptions for Skeletal Muscle Relaxants were subject to public review and comment and subsequently approved for implementation by the Department.

# PROCEDURE:

The procedures for prescribers to request prior authorization of Skeletal Muscle Relaxants are located in SECTION I of the Prior Authorization of Pharmaceutical Services Handbook. The Department will take into account the elements specified in the clinical review guidelines (which are included in the provider handbook pages in the SECTION II chapter related to Skeletal Muscle Relaxants) when reviewing the prior authorization request to determine medical necessity.

As set forth in 55 Pa. Code § 1101.67(a), the procedures described in the handbook pages must be followed to ensure appropriate and timely processing of prior authorization requests for drugs and products that require prior authorization.

# ATTACHMENTS:

Prior Authorization of Pharmaceutical Services Handbook - Updated pages

# **RESOURCES:**

Prior Authorization of Pharmaceutical Services Handbook – SECTION I Pharmacy Prior Authorization General Requirements <u>https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/Pharmacy-Prior-Authorization-General-Requirements.aspx</u>

Prior Authorization of Pharmaceutical Services Handbook – SECTION II Pharmacy Prior Authorization Guidelines https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/Clinical-Guidelines.aspx

# MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES

# I. Requirements for Prior Authorization of Skeletal Muscle Relaxants

# A. Prescriptions That Require Prior Authorization

Prescriptions for Skeletal Muscle Relaxants that meet any of the following conditions must be prior authorized:

- 1. A non-preferred Skeletal Muscle Relaxant. See the Preferred Drug List (PDL) for the list of preferred Skeletal Muscle Relaxants at: <u>https://papdl.com/preferred-drug-list</u>.
- 2. A Skeletal Muscle Relaxant with a prescribed quantity that exceeds the quantity limit. The list of drugs that are subject to quantity limits, with accompanying quantity limits, is available at: <u>http://www.dhs.pa.gov/provider/pharmacyservices/quantitylimitslist/index.htm</u>.
- 3. A Skeletal Muscle Relaxant that is subject to the U.S. Drug Enforcement Agency Controlled Substances Act (i.e., controlled substance) when the beneficiary has a concurrent prescription for a buprenorphine agent indicated for the treatment of opioid use disorder.

#### B. Review of Documentation for Medical Necessity

In evaluating a request for prior authorization of a prescription for a Skeletal Muscle Relaxant, the determination of whether the requested prescription is medically necessary will take into account the whether the beneficiary:

- 1. For a non-preferred Skeletal Muscle Relaxant, has a history of therapeutic failure, contraindication, or intolerance to the preferred Skeletal Muscle Relaxants approved or medically accepted for the beneficiary's diagnosis; **AND**
- 2. For a Skeletal Muscle Relaxant that is a controlled substance for a beneficiary with a concurrent prescription for a buprenorphine agent indicated for the treatment of opioid use disorder, **both** of the following:
  - a. Is prescribed the buprenorphine agent and the Skeletal Muscle Relaxant by the same prescriber or, if prescribed by different prescribers, all prescribers are aware of the other prescription(s)
  - b. Has an acute need for therapy with the Skeletal Muscle Relaxant;

# AND

- For a Skeletal Muscle Relaxant that is a controlled substance, has documentation that the prescriber or the prescriber's delegate conducted a search of the Pennsylvania Prescription Drug Monitoring Program for the beneficiary's controlled substance prescription history; AND
- 4. If a prescription for a Skeletal Muscle Relaxant is for a quantity that exceeds the quantity

# MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES

limit, the determination of whether the prescription is medically necessary will also take into account the guidelines set forth in the Quantity Limits Chapter.

NOTE: If the beneficiary does not meet the clinical review guidelines listed above but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary, the request for prior authorization will be approved.

# C. Clinical Review Process

Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B. above to assess the medical necessity of a prescription for a Skeletal Muscle Relaxant. If the guidelines in Section B. are met, the reviewer will prior authorize the prescription. If the guidelines are not met, the prior authorization request will be referred to a physician reviewer for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary.